Isoxazole, 30b | 747413-29-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子
• 英文名称: Isoxazole, 30b
• 英文别名: 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-[(2-methylsulfonylethylamino)methyl]phenyl]-1,2-oxazole-3-carboxamide
• CAS: 747413-29-2
• 化学式: C₂₂H₂₄ClN₃O₆S
• 分子量: 493.968
• InChiKey: HBZAMKDPZGODPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  150
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-N-ethyl-4-[4-[(2-methylsulfonylethylamino)methyl]phenyl]-1,2-oxazole-3-carboxamide 在 三氯化硼 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 Isoxazole, 30b
  参考文献：
  名称：

  4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer

  摘要：

  Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.

  DOI：

  10.1021/jm701018h

文献信息

• Isoxazole Compounds As Inhibitors Of Heat Shock Proteins
  申请人：Drysdale Martin James

  公开号：US20120252797A1

  公开（公告）日：2012-10-04

  Isoxazoles of formula (A) or (B) wherein R 1 is a group of formula (IB) The isoxazoles are inhibitors of HSP90 activity, and useful for the treatment of, for example, cancers.

  化合物的式子为(A)或(B)，其中R1为式子(IB)所代表的基团。这些异噁唑是HSP90活性的抑制剂，可用于治疗癌症等疾病。
• Isozazole Compounds As Inhibitors Of Heat Shock Proteins
  申请人：Drysdale Martin James

  公开号：US20100179138A1

  公开（公告）日：2010-07-15

  Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R 1 , is a group of formula (IA): —Ar 1 -(Alk 1 ) p -(Z) r -(Alk 2 ) s -Q, wherein in any compatible combination Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 6 alkylene or C 2 -C 6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NR A —, —C(═S)NR A —, —SO 2 NR A —, —NR A C(═O)—, —NR A SO 2 —or —NR A — wherein R A is hydrogen or C 1 -C 6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk 1 ) p -(Z) r -(Alk 2 ) s -Q wherein Q, Alk 1 , Alk 2 , Z, p, r and s are as defined above in relation to group (IA); and R 3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, or C 1 -C 6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

  式（A）或（B）的异噁唑是HSP90活性的抑制剂，可用于治疗癌症，例如：其中R1是以下式（IA）的基团：—Ar1-(Alk1)p-(Z)r-(Alk2)s-Q，其中在任何兼容的组合中，Ar1是可选取代的芳基或杂环芳基基团，Alk1和Alk2是可选取代的二价C1-C6烷基或C2-C6烯基基团，p，r和s独立地为0或1，Z为-0-，—S—，—（C═O）—，—（C═S）—，—SO.sub.2-，—C（═O）O—，—C（═O）NRA—，—C（═S）NRA—，—SO2NRA—，—NRAC（═O）—，—NRASO2—或—NRA—，其中RA为氢或C1-C6烷基，并且Q为氢或可选取代的碳环或杂环基团；R2为（i）上述式（IA）的基团或（ii）一个羧酰胺基团；或（iii）一个非芳香碳环或杂环环，其中一个环碳原子可选取代，和/或一个环氮原子可选取代为以下式的基团-(Alk1)p-(Z)r-(Alk2)s-Q，其中Q，Alk1，Alk2，Z，p，r和s如上所述定义于基团（IA）；和R3为氢，可选取代的环烷基，环烯基，C1-C6烷基，C1-C6烯基或C1-C6炔基；或羧基，羧酰胺基或羧酸酯基。
• Isoxazole compounds as inhibitors of heat shock proteins
  申请人：Vernalis (R&D) Ltd.

  公开号：US10413550B2

  公开（公告）日：2019-09-17

  Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NRA—, —C(═S)NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

  式（A）或（B）的异噁唑是 HSP90 活性的抑制剂，可用于治疗癌症等： -C(═O)O-、-C(═O)NRA-、-C(═S)NRA-、-SO2NRA-、-NRAC(═O)-、-NRASO2- 或 -NRA-，其中 RA 是氢或 C1-C6 烷基，Q 是氢或任选取代的碳环或杂环基；R2 是 (i) 上式 (IA) 的基团或 (ii) 羧酰胺基；或 (iii) 非芳香碳环或杂环，其中环碳任选被式-(Alk1)p-(Z)r-(Alk2)s-Q 的基团取代，和/或环氮任选被式-(Alk1)p-(Z)r-(Alk2)s-Q 的基团取代，其中 Q、Alk1、Alk2、Z、p、r 和 s 如上文有关基团 (IA) 的定义；和 R3 是氢、任选取代的环烷基、环烯基、C1-C6 烷基、C1-C6 烯基或 C1-C6 烷炔基；或羧基、羧酰胺或羧基酯基团。
• ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS
  申请人：Vernalis (Cambridge) Limited

  公开号：EP1611112B1

  公开（公告）日：2012-08-22
• US7705027B2
  申请人：——

  公开号：US7705027B2

  公开（公告）日：2010-04-27